- Home
- SCYX vs TBHC Comparison
SCYX vs TBHC Comparison
Compare SCYX & TBHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCYX
- TBHC
- Stock Information
- Founded
- SCYX 1999
- TBHC 1966
- Country
- SCYX United States
- TBHC United States
- Employees
- SCYX N/A
- TBHC N/A
- Industry
- SCYX Biotechnology: Pharmaceutical Preparations
- TBHC Other Specialty Stores
- Sector
- SCYX Health Care
- TBHC Consumer Discretionary
- Exchange
- SCYX Nasdaq
- TBHC Nasdaq
- Market Cap
- SCYX 26.6M
- TBHC 27.6M
- IPO Year
- SCYX 2014
- TBHC N/A
- Fundamental
- Price
- SCYX $0.88
- TBHC $1.24
- Analyst Decision
- SCYX
- TBHC
- Analyst Count
- SCYX 0
- TBHC 0
- Target Price
- SCYX N/A
- TBHC N/A
- AVG Volume (30 Days)
- SCYX 212.7K
- TBHC 406.0K
- Earning Date
- SCYX 08-19-2025
- TBHC 09-04-2025
- Dividend Yield
- SCYX N/A
- TBHC N/A
- EPS Growth
- SCYX N/A
- TBHC N/A
- EPS
- SCYX N/A
- TBHC N/A
- Revenue
- SCYX $2,630,000.00
- TBHC $431,111,000.00
- Revenue This Year
- SCYX $410.22
- TBHC N/A
- Revenue Next Year
- SCYX $248.83
- TBHC N/A
- P/E Ratio
- SCYX N/A
- TBHC N/A
- Revenue Growth
- SCYX N/A
- TBHC N/A
- 52 Week Low
- SCYX $0.66
- TBHC $1.20
- 52 Week High
- SCYX $1.82
- TBHC $1.73
- Technical
- Relative Strength Index (RSI)
- SCYX 68.89
- TBHC N/A
- Support Level
- SCYX $0.68
- TBHC N/A
- Resistance Level
- SCYX $0.92
- TBHC N/A
- Average True Range (ATR)
- SCYX 0.04
- TBHC 0.00
- MACD
- SCYX 0.02
- TBHC 0.00
- Stochastic Oscillator
- SCYX 83.33
- TBHC 0.00
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.